Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum Tolerated Dose (MTD)of CP-751,871 in Combination With Paclitaxel and Carboplatin: Phase 1b

Outcome Description:

The maximum tolerated dose of CP-751,871 in combination with paclitaxel and carboplatin is the highest dose level below the Maximum Administered Dose (the dose level at which 2 or more out of 3 to 6 patients experience a Dose Limiting Toxicity at a dose level in Cycle 1) at which none or one out of 6 patients experience a Cycle 1 Dose Limiting Toxicity.

Outcome Time Frame:

Start of treatment (baseline) up to the end of Cycle 1 (Day 21)

Safety Issue:

Yes

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A4021002

NCT ID:

NCT00147537

Start Date:

February 2005

Completion Date:

August 2011

Related Keywords:

• Carcinoma, Non-Small-Cell Lung
• non-small cell lung cancer
• chemotherapy
• figitumumab
• insulin-like growth 1 factor receptor
• IGF-IR
• monoclonal antibody
• Carcinoma
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms